Search research articles
Contact Us
Filters
Showing results (91-100 of 103) with videos related to
Page
of 11
Sort By:
Nature Communications
|
July 10, 2025
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, et al.
Nucleic Acids Research
|
January 9, 2016
Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence
Benjamin Sunkel, Dayong Wu, Zhong Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2009
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model
Evelien W Duiker, Elisabeth G E de Vries, Devalingam Mahalingam, et al.
Cancer Research Communications
|
June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Journal of the National Cancer Institute
|
May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Communications Medicine
|
May 21, 2024
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
Komal Jhaveri, Lisa D Eli, Sara A Hurvitz, et al.
Cardiovascular and Interventional Radiology
|
June 22, 2022
Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort
Aakash N Gupta, Andrew C Gordon, Ahmed Gabr, et al.
Oncotarget
|
August 11, 2016
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors
C Willemien Menke-van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 103) with videos related to
Sort By:
Page
of 11
Nature Communications
|
July 10, 2025
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, et al.
Nucleic Acids Research
|
January 9, 2016
Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence
Benjamin Sunkel, Dayong Wu, Zhong Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 12, 2009
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model
Evelien W Duiker, Elisabeth G E de Vries, Devalingam Mahalingam, et al.
Cancer Research Communications
|
June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Journal of the National Cancer Institute
|
May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Communications Medicine
|
May 21, 2024
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors
Jian Jenny Chen, Melanie Y Vincent, Dale Shepard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2026
Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
Komal Jhaveri, Lisa D Eli, Sara A Hurvitz, et al.
Cardiovascular and Interventional Radiology
|
June 22, 2022
Yttrium-90 Radioembolization of Unresectable Intrahepatic Cholangiocarcinoma: Long-Term Follow-up for a 136-Patient Cohort
Aakash N Gupta, Andrew C Gordon, Ahmed Gabr, et al.
Oncotarget
|
August 11, 2016
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors
C Willemien Menke-van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 20, 2023
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
Benedito A Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, et al.
Page
of 11